Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 130
- Registration Number
- NCT04276376
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 200
- Registration Number
- NCT04273061
- Locations
- 🇨🇦
BC Cancer, Vancouver, British Columbia, Canada
🇨🇦University Health Network / Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04267237
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT04262154
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇺🇸
Texas Oncology Cancer Center, Austin, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Blue Ridge Cancer Care, Roanoke, Virginia, United States
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 184
- Registration Number
- NCT04253145
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Cataluña, Spain
🇪🇸Hospital Universitario Da Coruña, A Coruña, Spain
🇪🇸Hospital Virgen del Rocio, Sevilla, Andalucia, Spain
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04250155
- Locations
- 🇳🇱
VU Medisch Centrum, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇪🇸Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
- Conditions
- Locally Advanced Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04249167
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 95
- Registration Number
- NCT04245085
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04221529
- Locations
- 🇦🇹
Klinikum Klagenfurt, Klagenfurt, Austria
🇩🇪St. Josef Hospital, Bochum, Germany
🇩🇪Klinikum Esslingen GmbH, Esslingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.